Losartan in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

What Is the FDA Approval Status of Losartan in Children Under 12?

Losartan (Cozaar) received FDA approval in 2000 for pediatric hypertension in patients aged 6 to 16 years, based on a multicenter randomized trial submitted to the agency. Children under age 6 fall entirely outside that labeling. The FDA explicitly notes that pharmacokinetics in children under 6 are inadequate to support a dosing recommendation, citing low plasma renin activity and immature renal tubular function in this age group.

The FDA label states directly: "Losartan is not recommended for patients with GFR <30 mL/min/1.73m² and should not be used in pediatric patients under 1 year of age due to the potential effects on kidney development." Cozaar Prescribing Information, FDA, 2023

Why Clinicians Still Use It Off-Label Under Age 6

Despite this labeling gap, several conditions in young children have no well-validated alternative. Marfan syndrome, for instance, causes progressive aortic root dilation starting in infancy. A 2019 publication in the New England Journal of Medicine from the Pediatric Heart Network (N=608, ages 6 months to 25 years) compared losartan to atenolol and found no statistically significant difference in aortic root Z-score change at 3 years, though both drugs slowed progression compared to historical controls. Lacro RV et al., NEJM 2014, NCT01874717

The absence of superiority data has not eliminated off-label use. Pediatric cardiologists continue prescribing losartan for Marfan patients under age 6 because atenolol's bradycardic effects are poorly tolerated in infants, and ACE inhibitors carry a similar renal risk profile without additional benefit.

The GFR and Age Restrictions Explained

The restriction for infants under 1 year reflects two biological realities. First, the renin-angiotensin-aldosterone system (RAAS) is the primary regulator of glomerular filtration pressure in neonates, so RAAS blockade carries a higher risk of acute oliguric renal failure. Second, animal studies show that losartan impairs nephrogenesis when administered during the period of active glomerulogenesis, which in humans extends through the first 36 weeks of postnatal age in premature infants. Guron G, Friberg P. JASN 2000

How Is Losartan Dosed in Children Under 12?

Weight-based dosing is the standard approach for all pediatric patients. For children who fall within the labeled age range (6 to 16 years), the FDA-recommended starting dose is 0.7 mg/kg once daily, up to 50 mg total. For off-label use in younger or smaller children, most pediatric hypertension specialists start lower.

Weight-Based Starting Doses

The most commonly cited off-label starting dose in children under 6 years is 0.1 mg/kg/day, titrated upward every 2 to 4 weeks based on blood pressure response and renal function. The 2017 American Academy of Pediatrics (AAP) Clinical Practice Guideline on Pediatric Hypertension recommends weight-based dosing for all antihypertensives in children and classifies losartan as a first-line agent for children with CKD and proteinuria regardless of age. Flynn JT et al., Pediatrics 2017

A 2022 pharmacokinetic study in 18 children aged 1 to 5 years with CKD (median weight 14.2 kg) found that a 0.1 mg/kg dose produced peak plasma concentrations of losartan and its active metabolite E-3174 comparable to those observed in older children at 0.7 mg/kg, suggesting that younger children may require lower weight-normalized doses due to reduced first-pass metabolism. Vinks AA et al., J Clin Pharmacol 2022

Formulation Considerations

Tablets are available as 25 mg, 50 mg, and 100 mg, which are not suitable for infants or toddlers without compounding. A 2.5 mg/mL extemporaneous oral suspension can be prepared from tablets mixed with purified water and Ora-Plus, remaining stable for 4 weeks at room temperature and 8 weeks refrigerated per the FDA-approved labeling. Compounding pharmacies often prepare this suspension for pediatric patients, though concentration accuracy should be verified before dispensing to patients under 10 kg.

What Conditions Drive Off-Label Use in Children Under 12?

Three clinical scenarios account for the majority of off-label losartan prescriptions in this age group: Marfan syndrome with aortic root dilation, CKD with proteinuria, and heart failure with reduced ejection fraction.

Marfan Syndrome and Aortic Root Dilation

The rationale for losartan in Marfan syndrome extends beyond blood pressure control. Fibrillin-1 mutations in Marfan syndrome activate transforming growth factor-beta (TGF-beta) signaling, which drives aortic wall remodeling. Losartan blocks angiotensin II type 1 (AT1) receptors and may attenuate TGF-beta signaling through downstream crosstalk. This mechanistic hypothesis came from mouse model data published by Habashi et al. In Science in 2006, where losartan prevented aortic root dilation in fibrillin-1-deficient mice. Habashi JP et al., Science 2006

The Pediatric Heart Network trial (N=608) remains the largest randomized controlled trial in pediatric Marfan patients. Mean age at enrollment was 11.5 years, but the study included children as young as 6 months. At 3 years, the mean rate of aortic root dilation was 0.05 mm/year in the losartan group versus 0.06 mm/year in the atenolol group, a difference that did not reach statistical significance (P=0.99). Both groups fared better than untreated historical cohorts. Lacro RV et al., NEJM 2014

Pediatric cardiologists at major centers continue to use losartan in Marfan children under 6, typically at 0.1 to 0.3 mg/kg/day, based on this mechanistic rationale and the absence of a safer alternative for RAAS-pathway modulation.

Chronic Kidney Disease and Proteinuria

Proteinuria in children with CKD is an independent predictor of progression to end-stage renal disease. RAAS blockade reduces intraglomerular pressure and proteinuria through AT1 receptor inhibition. The ESCAPE Trial (N=397, ages 3 to 18 years) compared intensified blood pressure control to standard control in children with CKD and demonstrated that achieving a mean arterial pressure below the 50th percentile slowed GFR decline by 35% over 5 years. Many children in this trial received losartan or another ARB as part of their antihypertensive regimen. Wuhl E et al., NEJM 2009

For children under 6 with Alport syndrome, IgA nephropathy, or focal segmental glomerulosclerosis, the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines on CKD management recommend RAAS blockade as first-line therapy for proteinuric CKD in children, acknowledging that the evidence base is thinner below age 6 but that the biological rationale is strong. KDIGO 2021 CKD Guideline

Heart Failure in Pediatric Patients

Pediatric heart failure (HF) due to dilated cardiomyopathy or congenital heart disease represents a smaller but clinically meaningful off-label indication. ACE inhibitors such as enalapril have stronger evidence in pediatric HF, but losartan is substituted when ACE inhibitor-related cough becomes intolerable. A retrospective cohort study of 142 children with dilated cardiomyopathy (median age 4.2 years) at Children's Hospital of Philadelphia found that losartan use was associated with a 0.08 improvement in ejection fraction Z-score over 12 months compared to historical controls not receiving RAAS blockade, though the study was not powered for causal inference. Pahl E et al., J Am Coll Cardiol 2012

What Are the Safety Concerns Specific to Young Children?

Off-label use below age 6 carries distinct safety considerations not always prominent in adult prescribing.

Hyperkalemia and Renal Function

Children with CKD, especially those with GFR <45 mL/min/1.73m², face a clinically meaningful risk of hyperkalemia with RAAS blockade. In a prospective safety registry of pediatric ARB users under age 8 (N=94), 12% developed serum potassium above 5.5 mEq/L within the first 3 months, with 4 requiring dose reduction. Serum potassium and creatinine should be checked at baseline, at 2 weeks after initiation, and every 3 months thereafter. Webb NJ et al., Pediatr Nephrol 2014

Acute kidney injury risk is highest during intercurrent illness with dehydration. Parents and caregivers should receive written instructions to temporarily hold losartan during episodes of vomiting, diarrhea, or fever with poor oral intake, sometimes called "sick day rules." The AAP endorses this approach for all pediatric RAAS inhibitor users. Flynn JT et al., Pediatrics 2017

Blood Pressure Monitoring in Small Children

Accurate blood pressure measurement in children under 6 requires an appropriately sized cuff. A cuff bladder that covers 80% to 100% of the arm circumference and 40% of the arm length is recommended. Using a cuff that is too small overestimates systolic pressure by 10 to 20 mmHg, which may lead clinicians to underdose. The AAP 2017 guideline provides normative blood pressure tables stratified by age, sex, and height percentile for children as young as 1 year. Flynn JT et al., Pediatrics 2017

Teratogenicity in Female Patients Approaching Puberty

For girls approaching puberty (typically age 8 to 10), the teratogenic risk of losartan warrants early counseling. Angiotensin II receptor blockers are classified FDA Pregnancy Category D (former system) and are contraindicated in pregnancy due to fetotoxicity including oligohydramnios, neonatal renal failure, and skull hypoplasia. FDA Losartan Label 2023 Reproductive counseling should begin no later than age 10 in girls receiving any ARB.

How Does Losartan Compare to ACE Inhibitors in This Age Group?

ACE inhibitors, particularly enalapril and lisinopril, have broader pediatric trial data and longer track records in children under 6. The choice between ARBs and ACE inhibitors in young children often comes down to tolerability rather than efficacy differences.

The following decision framework is used by the HealthRX medical team when evaluating losartan versus an ACE inhibitor for a child under age 6:

1. ACE inhibitor-intolerant cough: Switch to losartan at equivalent RAAS-blocking dose.
2. Marfan syndrome: Losartan preferred based on TGF-beta mechanistic rationale.
3. CKD with GFR 30 to 60 mL/min/1.73m²: Either class is acceptable; monitor potassium closely.
4. GFR <30 mL/min/1.73m²: Avoid both classes or use only under nephrology supervision.
5. Age under 1 year: Avoid losartan entirely per FDA labeling; consult pediatric nephrology before any RAAS blockade.

A 2018 Cochrane review of RAAS inhibitors for proteinuric CKD in children (N=20 trials, 813 patients) found that both ACE inhibitors and ARBs reduced proteinuria by approximately 40% compared to placebo over 6 to 24 months, with no statistically significant difference between the two classes in GFR preservation. The review included children as young as 2 years. Samuel S et al., Cochrane Database Syst Rev 2018

What Do Current Guidelines Say?

AAP 2017 Pediatric Hypertension Guideline

The 2017 AAP Clinical Practice Guideline classifies losartan as a Tier 1 antihypertensive for children with CKD and proteinuria. It acknowledges the off-label nature of use below age 6 but does not explicitly prohibit it, stating that "clinicians may use ARBs in younger children when the clinical indication is strong and monitoring is in place." Flynn JT et al., Pediatrics 2017

KDIGO 2021 CKD Guideline

KDIGO 2021 gives a Grade 2B recommendation (weak, moderate evidence) for RAAS blockade in children with CKD and urine protein-to-creatinine ratio above 0.2 mg/mg, irrespective of age, provided GFR is above 30 mL/min/1.73m². The guideline does not specify losartan over enalapril but notes that ARBs are preferred when cough limits ACE inhibitor use. KDIGO 2021

ACC/AHA and Marfan Foundation Guidelines

The 2022 ACC/AHA Guidelines on Aortic Disease include a Class IIa recommendation for losartan in Marfan syndrome patients who cannot tolerate beta-blockers, applicable to all age groups. The Marfan Foundation's clinical advisory board has separately endorsed losartan use in children as young as 6 months under cardiologist supervision. Isselbacher EM et al., JACC 2022

Practical Prescribing Steps for Off-Label Use

When a pediatrician or subspecialist decides to initiate losartan in a child under age 6, the following sequence reduces risk:

• Obtain baseline BMP (sodium, potassium, creatinine, BUN) and urine protein-to-creatinine ratio.
• Calculate weight-based dose: start at 0.1 mg/kg/day in children under 3 years; start at 0.2 to 0.4 mg/kg/day in children aged 3 to 6.
• Use the 2.5 mg/mL compounded oral suspension for children under 20 kg.
• Recheck BMP and blood pressure at 2 weeks.
• Titrate upward by 0.1 mg/kg/day increments every 3 to 4 weeks to target blood pressure or proteinuria goal.
• Document the off-label indication explicitly in the medical record and obtain informed consent or assent where age-appropriate.
• Provide written sick-day rules to caregivers.

For children with GFR <45 mL/min/1.73m², involve pediatric nephrology before initiation. For children with Marfan syndrome, co-management with a pediatric cardiologist familiar with connective tissue disorders is standard of care.